To examine whether efficacy of postoperative oral administration of UFT, a 5-fluorouracil derivative chemotherapeutic agent, may be influenced by incidence of apoptosis (apoptosis index) or apoptosis-related gene status (p53 and bcl-2) of the tumour, a total of 162 patients with pathologic stage I non-small cell lung cancer were retrospectively reviewed. UFT was administrated postoperatively to 44 patients (UFT group), and not to the other 118 patients (Control group). For all patients, 5-year survival rate of the UFT group (79.9%) seemed higher than that of the Control group (69.8%), although without significant difference (P = 0.054). For patients with higher apoptotic index, 5-year survival rate of the UFT group (83.3%) was significantly higher than that of the Control group (67.6%, P = 0.039); for patients with lower apoptotic index, however, there was no difference in the prognosis between these two groups. Similarly, UFT was effective for patients without p53 aberrant expression (5-year survival rates: 95.2% for the UFT group and 74.3% for the Control group, P = 0.022), whereas not effective for patients with p53 aberrant expression. Bcl-2 status did not influence the efficacy of UFT. In conclusion, apoptotic index and p53 status are useful factors to predict the efficacy of postoperative adjuvant therapy using UFT.
Non-small cell lung cancer (NSCLC) is a malignant tumour with poor prognosis, and the postoperative survival is not satisfactory (Mountain, 1997) . Although adjuvant therapy was introduced to improve the postoperative prognosis, it has been concluded that radiotherapy can not improve the survival although it can reduce the local recurrence rate. Therefore, systemic chemotherapy has been expected to improve the postoperative survival by suppressing occurrence of distant metastasis, and a variety of chemotherapeutic regimens have been attempted. However, the efficacy of postoperative adjuvant chemotherapy has not been established yet (Ihde et al, 1994) .
However, a recent retrospective study conducted by Kyoto University suggested that UFT administration was effective as a postoperative adjuvant therapy for NSCLC (Tanaka et al, 1998a) . UFT is an oral 5-fluorouracil (5-FU) derivative drug composed of tegafur (1-[2-tetrahydrofuryl]-5-fluoroiracil, FT) and uraci (U); tegafur is a pro-drug that persistently releases 5-FU, and uracil is added to inhibit degradation of the released 5-FU (Fujii et al, 1978; Ikenaka et al, 1979) . As a result, when UFT is administrated, certain 5-FU concentration in blood and tumour tissues can be maintained for a long time. The efficacy of postoperative oral administration of UFT was confirmed by a prospective randomized study conducted by 'The West Japan Study Group for lung cancer surgery'; 5-year survival rates of pathologic (p-) stage I-III, NSCLC were 64.1%, 60.6% and 49.0% in patients who received postoperative UFT administration (400 mg body Ϫ1 day Ϫ1 for one year after surgery, UFT group), in those who received the same UFT administration following intravenous infusion of CDDP (50 mg/m 2 body surface for one course) + VDS (2-3 mg kg body weight Ϫ1 for 3 courses) (CVUft group), and in those who received no adjuvant therapy (Control group), respectively (P = 0.044 among 3 groups, and P = 0.019 between the UFT group and the Control group) (Wada et al, 1996) . The efficacy of postoperative UFT administration in NSCLC was demonstrated in other prospective randomized studies (The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan), 1995; Wada et al, 1999) . Although these results suggest the efficacy of postoperative UFT administration, postoperative recurrence may appear in some cases even if UFT administration is performed. Thus, if whether UFT administration is effective or not can be predicted in an individual patient before the administration, postoperative prognosis can be improved when efficacy of UFT administration is expected, and medical and financial disadvantage of UFT administration can be relieved when the efficacy is not expected.
The p53 tumour suppressor gene protects the genome against a variety of damages, and suppresses occurrence of malignant tumour (Levine et al, 1991) . The p53 gene induces apoptosis as well as regulates the cell cycle (Clarke et al, 1993; Lowe et al, 1993) . Apoptosis is a kind of cell death distinct from necrosis, showing morphological features such as cell shrinkage, loss of cell-cell contact, chromatin condensation and intranucleosomal degradation of DNA (Kerr et al, 1972) . Apoptosis is an essential phenomenon for normal development and maintenance of homeostasis, and also plays an important role in suppressing proliferation of malignant tumour cells (Symonds et al, 1994; Holmgren et al, 1995) . It is known that apoptosis is induced by various anticancer agents and radiotherapy. Therefore, it has been reported that sensitivity to anticancer agents and radiotherapy can be influenced by the status of some genes associated with apoptosis such as the p53 gene (Clarke et al, 1993; Lowe et al, 1993) .
In a preliminary study, we have already reported that the efficacy of oral administration of FT and UFT after surgery for NSCLC may be influenced by p53 status (Tanaka et al, 1999a) . Moreover, we have already reported that balance between incidence apoptotic cell death and tumour-cell proliferation is an important factor to predict postoperative survival in resected NSCLC (Tanaka et al, 1999b) . In the present study, whether the efficacy of postoperative UFT administration was influenced by incidence of apoptosis (apoptotic index: AI) and by status of p53 and bcl-2 regulating apoptosis in more homogeneous patients (p-stage I patients) was examined.
PATIENTS AND METHODS
A total of 163 consecutive patients with p-stage I, NSCLC who underwent complete tumour resection and mediastinal lymph node dissection without any preoperative therapy at the Department of Thoracic Surgery, Kyoto University between January 1, 1987 and December 31, 1992, were reviewed. P-stage and histological typing were re-evaluated and determined according to the current TNM classification (Mountain, 1997) and the current classification by World Health Organization (Travis et al, 1999) , respectively. One patient was excluded from the study due to operation-related death, and thus a final total of 162 patients (122 males and 40 females) were evaluated. For all these patients, the inpatient medical records, chest X-ray films, whole-body CT films, bone and gallium scanning data and records of surgery were reviewed without knowledge of the results of immunohistochemical staining. Follow-up of the postoperative clinical course was conducted by outpatient medical records and by inquiries by telephone or letter. The day of thoracotomy was considered the starting day for counting postoperative survival days.
Clinical characteristics of patients
UFT was administrated to all patients in whom an informed consent had been taken; UFT was not administrated if not. As a result, among all 162 patients, UFT (Taiho Pharmaceutical Co, Tokyo, Japan) was administered to 44 patients (UFT group), and not administered to the other 118 patients (control group). Administration dose of UFT was 300 mg day Ϫ1 body Ϫ1 (body weight < 50 kg) or 400 mg day Ϫ1 body Ϫ1 (body weight ≥50 kg). Oral administration of UFT was initiated within one month after surgery. UFT was administered for at least one year if the patients were alive; for deceased patients, UFT was administered until oral administration became impossible. There were no significant differences in clinical characteristics of patients between the UFT group ant the control group (Table 1) . No other preoperative, intraoperative, or postoperative therapy was performed in any case.
Tissue preparation
Detection of apoptotic cells was performed with the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick endlabelling (TUNEL) method. Expression of PCNA (proliferating cell nuclear antigen), which was expressed in nucleus at the late G1 phase and S phase of the cell cycle, was examined immunohistochemically as an index of cell proliferation. Aberrant expression of p53 and expression of bcl-2 were also examined immunohistochemically. Serial 4-µm sections were prepared from each formalin-fixed and paraffin-embedded tumour specimen, and served for routine haematoxylin and eosin (H&E) staining, the TUNEL staining and immunohistochemical staining (IHS). Dewaxed sections were digested with 20 µg ml Ϫ1 proteinase K (Boehringer Manheim, Manheim, Germany) for 20 minutes at 25˚C for the TUNEL staining, and were heated in a microwave oven for 5 minutes three times for IHS. Endogenous peroxidase was inactivated by incubating the sections with 0.03% H 2 O 2 in methanol for 30 minutes at 25˚C. To reduce unspecific labelling, the sections were incubated with normal calf serum (DAKO Japan, Kyoto, Japan).
Detection of apoptosis
The TUNEL staining was performed using In Situ Death Detection Kit, POD (Boehringer Manheim, Manheim, Germany) following the manufactured protocol as described previously (Tanaka et al, 1999b) . The specificity of the TUNEL staining of apoptotic cells was confirmed by making the negative and the positive control slides at every staining. As negative control slides, sections incubated with the TUNEL reaction mixture without TdT were used. As positive control slides, sections treated with DNase 1 (0.7 mg ml -1 , Stratgene, La Jolla, CA) for 10 minutes at 25˚C before the TUNEL reaction were used. Apoptotic cells were determined with careful observation of TUNEL-staining sections and serial H&E-staining sections. TUNEL-positive staining cells that represent histological features of necrosis in H&E-staining sections were not considered to be apoptotic cells. In each case, a total of 10 000 tumour cells, 1000 tumour cells each in 10 different fields, were evaluated at high magnification (ϫ400) by two authors independently (F.T. and Y.O) without knowledge of clinical data. When a different evaluation of apoptotic cells was made, the field was re-evaluated until the evaluation coincided. The apoptotic index (AI) was defined as the number of apoptotic cells per 1000 tumour cells.
IHS
Procedure of IHS using streptoavidin-biotinylated horseradishperoxidase complex method (LSAB kit; DAKO JAPAN, Kyoto, Japan) was described previously (Tanaka et al, 1998b (Tanaka et al, , 1999a (Tanaka et al, , 1999b . Mouse anti-human PCNA, monoclonal antibody (MoAb) PC-10 (mouse IgG2a, kappa 400 µg ml Ϫ1 DAKO Japan) diluted at 1:50, anti-human p53 MoAb, clone DO-7 (mouse IgG2b, kappa, 250 µg ml Ϫ1 , DAKO Japan) diluted at 1:50, and anti-human bc1-2 MoAb, clone 124 (mouse IgG, kappa, 200 µg ml Ϫ1 , DAKO Japan) diluted at 1:50 and mouse were used as the primary antibody. Stained tissue slides were evaluated by two of the authors (F.T. and Y.O.) independently without knowledge of clinical data. A total of 1000 tumour cells were counted, and the percentages of positive cells were determined. When the percentage of positive-staining cells exceeded 5%, the slide was judged to exhibit aberrant expression of p53 or positive expression of bcl-2. The fraction of proliferative cells was represented by the percentage of PCNA-positive tumour cells (proliferative index: PI).
Statistical methods
Counts were compared by the chi-square test, and trends in counts were analysed by the chi-square test for trends. Continuous data were compared using Student's t-test if the distribution of samples was normal, or using Mann-Whitney U-test if the sample distribution was asymmetrical. Postoperative survival rate was analysed by the Kaplan-Meier method, and the difference was assessed by the log-rank test. Multivariate analysis of prognostic factors was performed using Cox's regression model. Differences were considered significant when P-value was less than 0.05. All statistical manipulations were performed using the SPSS for Windows software system (SPSS Inc, Chicago, IL, USA, 1993).
RESULTS

Incidence of apoptosis (AI), aberrant expression of p53 and expression of bcl-2
The mean AI for all patients was 19.2 ± 2.0 (mean ± standard error: SE), and the median AI was 10.9. There was no difference in the mean AI between the UFT group and the Control group (Table 1) . Even if the patients were divided to patients with higher AI (AI ≥ 10.9) and those with lower AI (AI < 10.9), there was no difference in ratios of higher and lower AI patients between the UFT group and the Control group. In 67 of 162 (41.4%) patients, p53 aberrant expression was demonstrated. In only 33 (20.4%) patients, bcl-2 was expressed. There was no significant difference in ratios of patients with p53 aberrant expression or in ratios of bcl-2-positive patients between the UFT group and the Control group (Table 1) .
Correlation of AI with cell proliferation, aberrant expression of p53 and expression of bcl-2
Correlation between AI and fraction of proliferative cancer cells (PI) was examined ( Table 2 ). The mean PI in higher-AI patients was 53.5%, which was significantly higher than that in lower-AI patients (31.6%). Moreover, the number of patients showing higher PI (PI ≥ 44%) was larger in higher-AI patients than in lower-AI patients. These results demonstrated that more cancer cells showing active proliferation have more chances of undergoing apoptosis. On the other hand, no significant correlation of AI with p53 aberrant expression or bcl-2 expression was observed.
AI, aberrant expression of p53 expression of bcl-2 and postoperative prognosis
According to univariate analysis of prognostic factors, 5-year survival rates of patients with and those without p53 aberrant expression were 60.4% and 80.1%, suggesting p53 aberrant expression was a significant factor to predict poor prognosis (P = 0.011). In contrast, no significant difference was observed in the prognosis between patients with and those without bcl-2 expression, or between patients with higher AI and those with lower AI (Table 3) . Multivariate analysis also confirmed that p53 aberrant Lower-AI: AI < 10.9 (median AI). Higher-AI: AI ≥ 10.9 (median AI). c expression was a significant factor to predict poor postoperative, and that bcl-2 expression or AI could not be a significant prognostic factor (Table 4) .
Efficacy of postoperative UFT administration and AI, aberrant expression of p53 and expression of bcl-2
5-year survival rates of the UFT group and the Control group were 79.9% and 69.8%, respectively. Although the UFT group seemed to show favourable prognosis as compared with the Control group, the difference proved not be significant (P = 0.054, Figure 1 ).
The efficacy of the UFT administration was compared between patients without and those with p53 aberrant expression. In patients without p53 aberrant expression, the UFT group showed significantly better prognosis than the Control group (95.2% and 74.3%, respectively, P = 0.022, Figure 2a) , demonstrating that UFT administration could improve the postoperative prognosis. In patients with p53 aberrant expression, however, there was no significant difference in the prognosis between the UFT group and the Control group (55.8% and 62.8%, respectively, P = 0.834, Figure 2b ), demonstrating that UFT administration was not effective in such cases. In contrast, there was no difference demonstrated in the efficacy of the UFT administration between patients with bcl-2 expression and those without bcl-2 expression, showing the efficacy of UFT was not influenced by the status of bcl-2 (Table 5) .
Concerning AI and the efficacy of UFT, in patients with lower AI, there was no significant difference in the prognosis between the UFT group and the Control group (5-year survival rates: 74.6% and 71.6%, respectively, P = 0.592, Figure 3a) , showing that UFT administration was not effective in lower-AI patients. On the other hand, in patients with higher AI, the UFT group showed significantly better prognosis than the Control group (5-year survival rates: 83.3% and 67.6%, respectively, P = 0.039, Figure 3b ), suggesting that UFT administration was effective in higher-AI patients.
To confirm the efficacy of UFT administration in patients without p53 expression and those with higher AI, multivariate analysis was performed among each patient-group. As a result, UFT administration proved to be an independent prognostic factor to improve the prognosis among patients without p53 aberrant expression (P = 0.030, relative risk (RR) and the 95% confidence interval (CI): 0.094 (0.011-0.799)), whereas not among patients with p53 aberrant expression (P = 0.830, RR and the 95% CI: 1.107 (0.439-2.787)). Similarly, UFT administration proved to be an independent prognostic factor to improve the prognosis among higher-AI (P = 0.032, RR and the 95% CI: 0.255 (0.068-0.900)), whereas not among lower-AI patients (P = 0.311, RR and the 95% CI: 0.599 (0.214-1.635)).
DISCUSSION
In the present study, it was suggested that efficacy of UFT administration as a postoperative adjuvant therapy for NSCLC might be influenced by incidence of apoptosis (AI) and status of p53 regulating apoptosis. UFT is a 5-FU derivative chemotherapeutic agent developed in Japan, and has been widely used in Japan Lower-AI: AI < 10.9 (median AI). Higher-AI: AI ≥ 10.9 (median AI).
c Lower-PI: PI < 44% (median PI). Higher-PI: PI ≥ 44% (median PI). mainly for malignant tumours originating from the digestive system. Recently, UFT has been introduced to clinical trials conducted in the United States. Pazdur and coworkers have already reported that UFT is effective to metastatic colorectal cancer when administrated with leucovorin (Pazdur et al, 1994) . Although 5-FU has been used as a basic chemotherapeutic agent for a variety of solid tumours, it has been reported that 5-FU is not effective to primary lung cancer. However, all these reports are based on results obtained by an intravenous bolus injection. Many experimental and clinical studies have revealed that 5-FU is not a dose-dependent but a time-dependent agent (Pinedo and Peter, 1988; Lokich et al, 1989) . Oral administration of 5-FU and the derivatives which can continuously maintain 5-FU concentration is an extremely useful method when the pharmacological features of 5-FU are considered (Fujii et al, 1978; Ikenaka et al, 1979) . UFT is inferior to other chemotherapeutic agents such as CDDP in terms of potency of direct anticancer activity. However, these chemotherapeutic agents with potent antitumour effect have not improved postoperative survival of NSCLC. The most important factor that worsens the prognosis of completely resected NSCLC patients is high incidence of distant metastasis after operation. Recently, it has been revealed experimentally that tumour growth was suppressed with induction of apoptosis in micrometastatic lesion (Holmgren et al, 1995) . We have also revealed clinically that the balance of apoptosis and proliferation of cancer cells influences on postoperative survival of NSCLC (Tanaka et al, 1999b) . Postoperative oral administration of UFT maintains a certain blood concentration of 5-FU, which may accelerate apoptosis of cancer cells in micrometastatic lesions without suppression of patients' immunity, resulting in improving the postoperative prognosis. Association of the efficacy of UFT with apoptosis is supported by the results obtained in the present study. In patients with higher AI, that is patients whose cancer cells can be easily induced to apoptotic death without treatment, UFT is effective as postoperative administration of UFT can suppress recurrence by accelerating apoptosis of cancer cells. On the other hand, in patients with lower AI, that is patients whose cancer cells can not be easily induced to apoptotic death, UFT administration can not regulate micrometastases by failure to induce such cancer cells to apoptosis. This speculation is consistent with results of basic experiments demonstrating that many anticancer drugs such as CDDP and 5-FU induce cancer cells to apoptosis (Sen and D'Incaki, 1992) .
The p53 gene is an important gene that regulates apoptosis. It has been demonstrated experimentally and clinically that the antitumour effect of chemotherapeutic agents was remarkably decreased if the p53 gene is mutated (Fujiwara et al, 1994; Lowe et al, 1994; Bergh et al, 1995) . These results are consistent with our results demonstrating that the efficacy of postoperative oral administration of UFT was diminished in patients with aberrant expression of p53, and are reasonably understandable when the function of p53 gene and apoptosis are considered. IHS employed in the present study to determine p53 status is clinically useful, because it is very easy and inexpensive as well as it can be performed on paraffin-embedded slides. However, accurate detection of p53 gene mutation can be achieved only when a complete sequence of the p53 gene is determined (Carbone et al, 1994) . In future study, correlation between efficacy of UFT and the presence of p53 gene mutation should be examined.
The bcl-2 gene was cloned as a gene that prolongs a cellular life by inhibiting apoptosis. Although there has been many reports on significance of bcl-2 expression in NSCLC, a definite conclusion has not yet been established (Pezzella et al, 1993; Pastorino et al, 1997) . Because the incidence of bcl-2 expression in NSCLC is as low as about 20%, the significance of bcl-2 expression as a prognostic factor and a predictive factor of therapeutic effect may not be important. In future, to clarify significance of p53 aberrant expression detected with IHS and incidence of apoptosis (AI) in association with the efficacy of postoperative oral administration of UFT, prospective randomized study on the UFT administration stratified by the p53 status and AI should be conducted. Lower-AI: AI < 10.9 (median AI). Higher-AI: AI ≥ 10.9 (median AI). 
